Yi, TW;
Wong, MMY;
Neuen, BL;
Arnott, C;
Poirier, P;
Seufert, J;
Slee, A;
... Levin, A; + view all
(2023)
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Diabetes, Obesity and Metabolism
10.1111/dom.15065.
Preview |
Text
Effects of canagliflozin on cardiovascular and kidney events.pdf - Published Version Download (619kB) | Preview |
| Type: | Article |
|---|---|
| Title: | Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/dom.15065 |
| Publisher version: | https://doi.org/10.1111/dom.15065 |
| Language: | English |
| Additional information: | © 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| Keywords: | SGLT2 inhibitor, canagliflozin, cardiovascular disease, type 2 diabetes |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10169867 |
Archive Staff Only
 |
View Item |
